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Abstract 12 
A strict gluten-free diet is currently the only treatment for the 1-2% of the world population who suffer 13 
from coeliac disease (CD). However, due to the presence of wheat and wheat derivatives in many food 14 
products, avoiding gluten consumption is difficult. Gluten-free products, made without wheat, barley 15 
or rye, typically require the inclusion of numerous additives, resulting in products that are often less 16 
healthy than gluten-based equivalents. Here, we summarise and contrast two broad approaches to 17 
decrease wheat gluten immunogenicity for CD patients. The first is based on food processing 18 
strategies, which aim to remove gliadins or all gluten from edible products. We find that several of the 19 
candidate food processing techniques to produce low gluten-immunogenic products from wheat 20 
already exist. The second approach focuses on wheat breeding strategies to remove immunogenic 21 
epitopes from the gluten proteins, whilst maintaining their food-processing properties. A combination 22 
of breeding strategies, including mutation breeding and possibly genome editing, will be necessary to 23 
produce coeliac-safe wheat. Individuals suffering from CD and people genetically susceptible who 24 
may develop CD after prolonged gluten consumption would benefit from reduced CD-immunogenic 25 
wheat. Although the production of healthy and less CD-toxic wheat varieties and food products will be 26 
challenging, increasing global demand may require these issues to be addressed in the near future by 27 
food processing and cereal breeding companies. 28 
 29 
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 32 
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1. Introduction 34 
Wheat forms the basis of a diverse range of staple foods globally, which includes bread and bakery 35 
items in addition to other products such as alcoholic beverages and food additives. Two major storage 36 
protein families are present in wheat grains: glutenins and gliadins (belonging to glutelins and 37 
prolamins, respectively), which are collectively known as gluten. The qualitative and quantitative 38 
properties of wheat gluten are important factors for baking quality. Despite its predominance in the 39 
human diet, wheat can cause allergies and/or intolerances after consumption in susceptible individuals 40 
(Fasano, 2006). Wheat contains immunogenic proteins, but the prevalence of wheat allergy, which is 41 
mediated by IgE antibodies, is low (Zuidmeer et al. 2008; Gilissen et al. 2014). However, gluten can 42 
also trigger intolerance reactions in 1-2% of the human population, the most common of which is 43 
coeliac disease (CD) (Mäki et al. 2003; Rewers 2005; Catassi et al. 2014; Vriezinga et al. 2015). 44 
CD is a chronic inflammation of the small intestine, which leads to a variety of symptoms that can 45 
include malnutrition, bowel disorders, skin, bone, nerve, and muscle problems. It is induced by 46 
epitopes (peptide sequences of nine amino acids) present in gluten proteins from wheat, barley and 47 
rye. These epitopes are bound by human leucocyte antigen sub-units (HLA-DQ2 or HLA-DQ8) 48 
located on antigen presenting cells in humans, which are subsequently recognised by T cells, 49 
triggering an immune reaction (for reviews see Fasano 2009; Koning 2012). CD develops in 50 
genetically predisposed individuals, and is induced by gluten ingestion. A strict gluten-free diet is 51 
currently the only treatment to stop the immune reaction and inflammation, allowing the intestine to 52 
recover, after which the symptoms gradually disappear. 53 
Avoiding consumption of gluten is difficult to do in practice, due to the presence of wheat derivatives 54 
in many supermarket products (Atchison et al. 2010). Therefore there is a need for new strategies to 55 
create food products with low gluten immunogenicity. Here, we summarise several strategies to 56 
decrease wheat gluten toxicity for CD patients, based on food processing and on wheat breeding 57 
(Figure 1). The food processing strategies aim at removing gliadins or whole gluten from edible 58 
products (Gilissen et al. 2016b) whereas the wheat breeding strategies focus on the removal of 59 
immunogenic epitopes from the gluten proteins, whilst potentially maintaining their food-60 
technological properties (Smulders et al. 2015; Shewry and Tatham 2016). If successful, the latter 61 
strategy may result in food products considered coeliac-safe, despite containing large amounts of 62 
gluten, which would require alternative labelling from the term ‘gluten-free’. A comparison of the 63 
applicability of these approaches, in terms of technical and economic aspects, is presented. Two 64 
groups of people may benefit especially from food products derived from such reduced CD-65 
immunogenic wheat: (1) individuals suffering from CD, whether they are already or not yet diagnosed 66 
as CD patient, and (2) genetically predisposed individuals who may develop CD after prolonged wheat 67 
or gluten consumption. 68 
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2. Food processing-related strategies to manufacture gluten-free products or to 70 
lower the content of CD epitopes 71 
Wheat gluten is a polymer composed of two types of proteins: glutenins and gliadins. The type of 72 
HMW subunits and the ratio of glutenins and gliadins determine the viscoelasticity properties required 73 
for bread, cakes or other baking products (Weegels et al. 1996; Shewry et al. 2009). The high and low 74 
molecular weight glutenin subunits (HMW-glutenins and LMW-glutenins) form a strong glutenin 75 
macro polymer (GMP) network, formed by inter-chain disulphide bonds, which determines dough 76 
elasticity. The monomeric gliadin proteins (α/β-gliadins, γ-gliadins and ω-gliadins) are linked to the 77 
GMP and can be envisaged to ‘dilute’ the strength of the GMP, thus influencing dough viscosity 78 
(Shewry 2009). The glutenins are the less immunogenic gluten proteins for CD. The monomeric 79 
gliadin proteins (α/β-gliadins, γ-gliadins and ω-gliadins) are the most immunogenic.  80 
Two types of products can be generated during food production: gluten-free products made without 81 
ingredients from wheat, barley or rye (Figure 1a), or products with low gluten immunogenicity based 82 
on the processing of these cereal grains to remove the immunogenic gluten fraction (Figure 1b) (as 83 
reviewed by Kucek et al. 2015). Food products can be labelled as ‘gluten-free’ as long as they contain 84 
less than 20 ppm of gluten (Saturni et al. 2010). 85 
 86 
2.1. Gluten-free products made without ingredients from wheat, barley and rye  87 
With increasing numbers of patients with CD being diagnosed, the gluten-free market is becoming 88 
more important, and gluten-free products are increasingly found on grocery shop shelves. Such 89 
products generally do not contain any wheat, barley or rye, but include several additives (Figure 1a) to 90 
recreate the viscoelastic properties of gluten present in these cereal grains (as summarised by 91 
Gustafson 2016). 92 
Current composition of gluten-free products 93 
Currently commercial gluten-free bread is usually made from a mixture of flours, including maize, 94 
rice, sorghum and oat. Oat can be consumed safely by CD patients without a daily limit (Kaukinen et 95 
al. 2013; Hardy et al. 2015; Gilissen et al. 2016a and references therein). Alternatively, flour from 96 
pseudo-cereals (such as amaranth, buckwheat and quinoa), legumes and nuts have been proposed as 97 
new candidates for gluten-free products.  98 
Issues encountered with these gluten-free flours are their lack of viscoelasticity and their low ability to 99 
retain water and CO2, the properties responsible for dough rising conferred by the gluten network. 100 
Starch may be added to increase viscosity and provide some binding abilities to the dough. Starches 101 
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from potato, corn, rice and cassava (tapioca) are mostly used. Hydrocolloids, also known as gums, are 102 
also important additives in gluten-free baking products. They are used as substitute for glutenins to 103 
confer elasticity to the dough, as well as gas and moisture retention for higher loaf volumes and longer 104 
shelf life. Inulin, xanthan, guar gum, and hydroxypropyl methylcellulose (HPMC) are the most 105 
commonly used hydrocolloids in gluten-free bread. Protein concentrates such as soybean, egg and 106 
whey proteins are also used for their gelling properties, contributing to dough quality improvement. 107 
The addition of lipids, such as sunflower and safflower oil, retards the staling process, due to the gas-108 
retaining properties of polar lipids (Horstmann et al. 2016). Additionally, emulsifiers such as glycerol 109 
monostearate and lecithin are commonly used to reduce staling and to increase shelf-life. Sodium 110 
stearoyl-2-lactylate is also an emulsifier but acts by stretching the gluten network. High salt content is 111 
often used to improve taste, texture and bread stability (Belz, 2016).. The addition of dietary fibre 112 
through incorporation of oat or rice bran could become a solution to compensate for the low fibre 113 
content of gluten-free bread (Gilissen et al. 2016b). Rice bran also appears to improve rheology and 114 
sensory aspects of gluten-free bread, whereas dough acidification with acetic, citric, or lactic acid, or 115 
monosodium phosphate can also help improve bread volume.  116 
 117 
Health issues associated with current gluten-free products 118 
Gluten-free bread thus contains far more additives than standard wheat bread. As a result, regular 119 
consumption of gluten-free bread may in itself cause health issues, e.g. the mineral content can be very 120 
low, leading to iron and calcium deficiency, and despite the inclusion of protein additives for dough 121 
improvement, it is a relatively poor source of protein. Gluten-free bread is usually low in fibre, which 122 
decreases the sensation of satiety; in contrast, it is rich in starch, thereby enhancing the risk of 123 
hyperglycaemia and diabetes. Gluten-free bread also contains high levels of salt, which is a risk for 124 
cardiovascular and renal disease. In addition to being high in lipids, gluten-free products contain trans 125 
fatty acids, which may provoke metabolic imbalance (Caponio et al. 2008). Several countries try to 126 
reduce or eliminate them from food products. Fructan-type inulin is used in gluten-free bread as a 127 
hydrocolloid but is known to be a possible cause of irritable bowel syndrome (IBS) (Capriles and 128 
Arêas, 2014). IBS is mainly caused by fermentable oligosaccharides, disaccharides, monosaccharides 129 
and polyols (FODMAPs) such as fructan, a fructose polymer. Since fructans are present in the wheat 130 
grain, IBS is often associated with wheat as non-coeliac gluten sensitivity or non-coeliac wheat 131 
sensitivity (NCGS), and is sometimes wrongly auto-diagnosed as CD. While a low FODMAPs diet 132 
will usually decrease IBS symptoms, some gluten-free bread products containing inulin may not be 133 
suitable for these patients. In such cases, it is important to be diagnosed with the correct disorder. 134 
Nonetheless, based on the frequency of people with clinical bowel complaints that appear to improve 135 
under a gluten-free diet, the prevalence of NCGS might be as high as 6% of the population (Gilissen et 136 
al. 2014), but more recent evidence suggests that ‘true’ NCGS is only slightly more than 1% of the 137 
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population (Catassi 2015). Although no biomarkers have been identified yet, a state of systemic 138 
immune activation in conjunction with a suggested compromised intestinal epithelium could be 139 
observed in a subset of individuals with NCGS (Uhde et al. 2016). In addition to individuals 140 
diagnosed with CD or IBS, other consumers have actively decided to avoid wheat and gluten based on 141 
personal choice. However, such choices are often made following self-diagnosis based on personal 142 
health-related preference, rather than for clear medical reasons, despite the dietary concerns described 143 
above.  144 
 145 
Gluten contamination elimination diet (GCED) 146 
Some coeliac patients have persistent symptoms and villous atrophy despite strict adherence to a 147 
gluten-free diet. They are referred to as having ‘non-responsive CD’. Some non-responding CD 148 
patients may react to minute amounts of gluten, likely present as contaminants in processed gluten-149 
free foods. For example, industrial conversion of wheat starch into other food-grade carbohydrates 150 
may not eliminate all gluten (Scherf et al. 2016). Therefore, foods containing these modified 151 
carbohydrates may still contain very low levels of stable, and potentially immunogenic, gluten. 152 
Furthermore, when chemically deamidated gluten protein, which is even more immunogenic than 153 
natural gluten proteins, is used for increased emulsifying applications (Wu et al. 1976) it may be 154 
undetectable in the R5 monoclonal antibody assay used for routine gluten screening by commercial 155 
companies (Kanerva, 2011). These undetected deamidated gluten fractions can also contribute to 156 
contamination of food labelled as ‘gluten-free’.   157 
Over 80% of the non-responsive patients showed health improvement under a ‘gluten contamination 158 
elimination diet’ (GCED), that includes only fresh and unprocessed foods. These patients were able to 159 
return to a traditional gluten-free diet without return of symptoms (Hollon et al. 2015). A subset of 160 
‘non-responsive CD’ patients do not show any decrease in symptoms under GCED, and therefore 161 
suffer from true ‘refractory CD’ (RCD).  162 
 163 
2.2. Development of wheat-based products with low gluten immunogenicity  164 
Due to the low dietary value and health risks associated with non-wheat based gluten-free products, 165 
alternative food processing methods for wheat are being investigated (Figure 1b). The main aim is to 166 
use wheat (conserving the rheological properties conferred by the glutenins), whilst removing the most 167 
immunogenic gluten fraction (the gliadins). This approach would decrease the need for additives to 168 
reach adequate dough quality and dietary values, thus improving the healthiness of gluten-free or 169 
‘gluten-safe’ products.  170 
 171 
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Malting 172 
The malting process is not only relevant for brewing beer, but also for the baking sector. Malting 173 
represents the first step in seed germination, during which amylase enzymes become active, degrading 174 
starch into maltose to provide the source of energy for the embryo to germinate. Malting produces 175 
higher amounts of maltose, which enhances further fermentation. In addition, endogenous proteolytic 176 
enzymes in the grain degrade storage proteins (i.e. gluten), releasing amino acids that are used by the 177 
growing seedling. Gliadins become degraded through the activity of proteases (Bigiarini et al. 1995). 178 
Because of this degradation process, in practice many brands of beer are technically gluten-free or 179 
contain only small amounts of gluten. 180 
Malting has been used for many years to add flavour and crust colour to bread, and can even enhance 181 
sourdough fermentation when the malting process is not fully stopped. It has been shown that malted 182 
and fermented wheat sourdough effectively degrade 95% of the gliadins (Loponen et al. 2007), 183 
leading to bread that is low in gliadins. An alternative approach is the use of enzyme extracts from a 184 
small stock of germinated seeds (particularly barley seeds). This has recently been suggested to be 185 
applicable to the large-scale production of flour with a reduced gliadin content (Stenman et al. 2010; 186 
Schwalb et al. 2012).  187 
 188 
Sourdough fermentation and dough acidification 189 
Sourdough is the result of the activity of micro-organisms (Lactobacilli and yeast) naturally present in 190 
flour, becoming active when water is added. Lactobacillus ferments the flour/water mixture creating 191 
lactic acid, acidifying the mixture. This enhances the activity of propyl endopeptidase (PEP) enzymes 192 
produced by other micro-organisms to degrade gluten proteins (Hartmann et al. 2006; Gänzle et al. 193 
2008; Loponen et al. 2009). Sourdough fermentation has been suggested as a way of enabling the 194 
manufacture of ‘gluten-free’ or ‘low-in-gluten’ (< 100 ppm) wheat-based products through proteolytic 195 
gluten degradation (Loponen, 2006). Similarly, chemical acidification of conventional dough has been 196 
shown to activate PEP activity, resulting in increased prolamin degradation (Kanerva, 2011), although 197 
not as much as in traditional sourdough. However, artificially acidified dough may trigger more 198 
intestinal permeability (Di Cagno et al. 2004) and enhance non-enzymatic deamination of gluten 199 
peptides, which may render them more immunogenic (Arentz-Hansen et al. 2000).  200 
Sourdough fermentation is a traditional baking process with a long history, particularly in Germany. 201 
The prevalence of CD in Germany (measured using a single antibody test) has been found to be 202 
remarkably low, 0.4% and 0.2% in women and men, respectively (Kratzer et al. 2013), confirming 203 
earlier data showing a 0.1-0.4% prevalence on the basis of anti-tTG and anti-endomysial antibody 204 
(EMA-IgA) tests (Mustalahti et al. 2010). Recent estimations of the celiac prevalence in Germany 205 
have increased to 0.8%, especially in children and young adults up to 17 years old (Laass et al. 2015). 206 
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This may reflect under-diagnosis in earlier studies. However, if sourdough indeed reduces the 207 
exposure to intact gluten epitopes, then the recent increase in CD prevalence in young people may 208 
reflect a change in the diet of German children towards white and yeast-based bread. 209 
Recently, Greco et al. (2011) described a two-step hydrolysis including fungal proteases and 210 
Lactobacillus endo-peptidase activity, which resulted in a wheat flour-derived product with less than 211 
10 ppm gluten. This product was found not to be harmful to CD patients (Greco et al. 2011). These 212 
observations are promising, but further research on the potential of sourdough products in a safe 213 
‘gluten-free’ diet is needed, examining individual cases. Firstly, a strict definition on the type of 214 
sourdough is required, and the process of gluten degradation needs to be analysed in detail. Secondly, 215 
it needs to be determined whether large-scale consumption by the general population of well-defined 216 
sourdough products can indeed contribute to the reduction of the incidence and symptom severity of 217 
CD and NCWS. This will require large-scale epidemiological studies. 218 
 219 
Degradation of gluten using a peptidase 220 
Walter et al. (2014) showed that AN-PEP, an Aspergillus niger prolyl endopeptidase, can be used to 221 
degrade gluten in wheat bran to below 20 ppm. Such treated wheat bran could have a use in increasing 222 
the nutritional value of the gluten-free diet, e.g. by increasing soluble fibre content.  223 
 224 
Separation of gliadins from total gluten  225 
Extraction of HMW-glutenins from total gluten and substitution of the highly immunogenic wheat 226 
gliadins with, for instance, coeliac-safe oat avenins in order to maintain good baking quality (Van den 227 
Broeck et al. 2011), is a realistic option in foods aiming at a strongly reduced immunogenic gluten 228 
load. Nearly complete separation can be achieved at the lab scale (Bassi et al. 1997; Gilissen et al. 229 
2012; Lagrain et al. 2013). Industrial scale-up to economically and technologically viable levels 230 
appears to be more problematic, and would need further research. Alternatively, α-gliadins, the most 231 
immunogenic gluten proteins, can be partially removed mechanically using roller-milling to remove 232 
the seed sub-aleurone layer, in which a large fraction of the α-gliadins are deposited (van Herpen et al. 233 
2008; Sutton et al. 2015). 234 
 235 
Reduction of the use of vital gluten 236 
Vital (or purified) wheat gluten is a major side-product of wheat starch production. Starch is used to 237 
make native and modified starch, glucose syrup, maltodextrins, and liquid and crystalline polyols, with 238 
wide applications in the food industry. Wheat starch is also used for the production of alcohol, 239 
including bioethanol. Since wheat starch is economically more important than flour for bakery 240 
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purposes, vital gluten production (as side-product of starch isolation) is large, and its cost relatively 241 
low. 242 
Vital gluten is increasingly applied as a protein additive in food products to improve technological 243 
characteristics. In bread and bakery products vital gluten is added to maintain high loaf volumes, but 244 
most of its use is in the form of a ‘hidden’ ingredient, often not labelled, in a large number of 245 
processed food products. This may have contributed to the increase in total gluten consumption: 246 
between 1977 and 2007, gluten intake in the western world has tripled (Kasarda, 2013). Currently, a 247 
‘back to basics’ philosophy in modern bakeries in The Netherlands has led to ‘clean label’ strategies, 248 
and avoidance (or strong reduction) of bread quality-improving ingredients such as enzymes and vital 249 
gluten in artisanal and industrial whole grain breads. There is, however, no indication of a reduction in 250 
the use of vital gluten in other food production sectors.  251 
 252 
3. Wheat breeding strategies for products with low gluten immunogenicity 253 
(‘coeliac-safe wheat’) 254 
An alternative strategy for the production of gluten-free wheat-based food is to develop wheat 255 
varieties with fewer or no immunogenic CD epitopes (Figure 1c) (Gilissen et al. 2008; Shewry and 256 
Tatham 2016). To be able to generate such varieties, one must be aware of the complexity of wheat 257 
genome and the structure of gene families coding for gliadin immunogenic CD epitopes. 258 
 259 
3.1. Wheat breeding background: genomics, gluten gene families and gliadin protein 260 
epitopes 261 
The ancestor of all wild and cultivated wheat species was a diploid grass (2n=14), which evolved into 262 
several diploid species (e.g. Goncharov, 2011; Goryunova et al. 2012). Natural allopolyploidisation 263 
occurred through hybridisation between the diploid species Triticum urartu (AA genome) and 264 
Aegilops speltoides (BB or SS) followed by chromosome doubling, resulting in tetraploid emmer 265 
wheat, T. turgidum spp. dicoccoides (AABB). Much later, tetraploid emmer hybridized with goat 266 
grass, Aegilops tauschii (DD), followed by chromosome doubling, resulting in hexaploid bread wheat, 267 
Triticum aestivum (AABBDD) (Gupta et al. 2008). The latter allopolyploidisation took place in 268 
agricultural fields early after the start of cultivation of emmer wheat; bread wheat does not exist in 269 
nature. 270 
The α-gliadins are encoded by a large gene family of perhaps 150 genes, located on the short arms of 271 
the group 6 chromosomes (6AS, 6BS and 6DS) (Shewry et al. 2003). The γ-gliadins, ω-gliadins and 272 
LMW-glutenins are encoded by gene families located on the short arms of the group 1 chromosomes 273 
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(1AS, 1BS and 1DS), while the HMW-glutenins are encoded by gene families located on 1AL, 1BL 274 
and 1DL. 275 
The presence of the D genome in hexaploid T. aestivum provides additional gluten proteins, which 276 
considerably improve its bread baking properties compared to tetraploid wheat, particularly HMW-277 
glutenin subunits (Payne et al. 1984). However, the D genome also encodes for gliadins that have been 278 
reported as highly immunogenic.  279 
CD epitopes are 9 amino acids in length, and form the peptide fragment that fits into the T cell HLA-280 
DQ2 and HLA-DQ8 epitope-presenting receptor grooves. The list of well-defined CD epitopes (Sollid 281 
et al. 2012) comprises: twenty-four DQ2 epitopes and seven DQ8 epitopes, including six epitopes 282 
present in α-gliadins and eleven in γ-gliadins, complemented by two ω-gliadin epitopes, three LMW-283 
glutenin, and two HMW-glutenin epitopes. The HLA-DQ8 epitopes play a minor role in the 284 
development of CD, since over 90% of CD patients are HLA-DQ2 positive and react to α-gliadins 285 
(Koning, 2012; 2015). The HLA-DQ / gliadin peptide / T cell interactions have been characterised 286 
extremely well. The positions that are crucial for immune reactivity of α-gliadins, identified by T cell 287 
tests (e.g., Mitea et al. 2010), correspond exactly with the amino acid residues that form the crucial 288 
hydrogen bridges that connect HLA-DQ2 (Petersen et al. 2014) to the T cell receptor, a connection 289 
which, if sufficiently stable, triggers the immune reaction in humans. The structure of the HLA-DQ8 / 290 
gliadin peptide / T cell interaction has also been characterised in detail (Petersen et al. 2016). 291 
At the genomic level, the occurrence of CD epitopes varies between gliadin genes (each locus 292 
comprising multiple gene copies), between homoeologous wheat chromosomes (A, B, D), and among 293 
wheat varieties and species (Spaenij-Dekking et al. 2005; Molberg et al. 2005; van Herpen et al. 2006; 294 
Salentijn et al. 2009; 2012; van den Broeck et al. 2010a; 2010b). The α-gliadins from the D genome 295 
contribute most CD epitopes, while those from the B genome contribute the least (van Herpen et al. 296 
2006; Salentijn et al. 2009). For γ-gliadins, the highest number of CD epitopes has also been found in 297 
genes present on the D genome (Salentijn et al. 2009; 2013). While less sequence information is 298 
available for ω-gliadins, their involvement in CD immunogenicity has been recently recognized from 299 
cross-reactivity of T cells with rye and barley epitopes (Tye-Din et al. 2010).  300 
We will first discuss research approaches aimed at identifying naturally occurring variation within 301 
gliadin gene sequences and loci. This genetic variation can be used in conventional breeding and 302 
forward genetics approaches, by introgression into new wheat varieties. However, there is limited 303 
prospect for success, as multiple gliadin loci occur in the polyploid wheat genome, and glutenins and 304 
gliadins are encoded by large gene families, so multiple genes need to be screened. Many of the genes 305 
are closely linked in the genome, which limits the frequency of recombination, making selection of 306 
appropriate variation through a breeding approach difficult. Therefore, the use of reverse genetics 307 
approaches, such as random or directed mutagenesis and transgenic methods (such as gene silencing) 308 
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or gene editing are considered attractive options to create wheat varieties with reduced gluten 309 
immunogenicity. We will discuss such approaches later in this review. 310 
When these approaches lead to wheat varieties with fewer gliadin proteins, this may affect baking 311 
quality. The effect should be compensated for, and one approach is the addition of celiac-safe proteins 312 
that perform the same function in the GMP (Gilissen et al. 2012, Smulders et al. 2015), as was 313 
demonstrated for oat avenins added to flour of wheat deletion lines lacking certain groups of gliadins 314 
(Van den Broeck et al. 2009). 315 
 316 
3.2. Selection of low CD-toxic wheat accessions and varieties 317 
Genebanks around the world contain modern and old varieties of hexaploid and tetraploid wheat 318 
varieties, as well as landraces (locally adapted wheat accessions), wild emmer (Triticum dicoccoides) 319 
and wild diploid species that are related to the ancestors of cultivated wheat (crop wild relatives). 320 
These collections are a useful source of wheat germplasm for analysing the relationships between 321 
individual gluten genes or proteins, the occurrence of epitope variants, and the resulting CD 322 
immunogenicity. 323 
Whilst there may be large variation in the presence of intact CD epitopes amongst individual α-gliadin 324 
genes, all wheat varieties or accessions express multiple gliadins (Salentijn et al. 2013), which reduces 325 
the variation detected between varieties by immunogenic screening approaches. Indeed, screening 326 
with monoclonal antibodies (mAbs) for two CD epitopes revealed limited genetic variation in gliadins 327 
immunogenicity among modern wheat varieties (van den Broeck et al. 2010a). Some older hexaploid 328 
wheat varieties were identified with somewhat lower mAb response, as well as two lines derived from 329 
a heterogeneous tetraploid durum wheat landrace (van den Broeck et al. 2010b). In addition, analysis 330 
of nine landraces of farro wheat (T. turgidum ssp. dicoccum) revealed three landraces that caused 331 
negligible proliferation of T-cell lines from CD patients, whereas the other landraces studied showed 332 
intermediate to very high responses (Vincentini et al. 2009). 333 
Diploid einkorn wheat (T. monococcum, A genome) has good nutritional characteristics and bread 334 
making quality. Food products made from the variety ‘Monlis’ have been shown to be tolerated by CD 335 
patients, revealing similar absence of CD toxicity-related symptoms as found for rice (Zanini et al. 336 
2013). New combinations of gluten genes can be made by crossing and selection at the diploid level. 337 
Although this is a time-consuming procedure, the increasing incidence of CD in recent decades would 338 
justify selection for reduced CD epitopes levels as a novel quality trait for wheat breeding (van den 339 
Broeck et al. 2011). 340 
The utility of screening wheat germplasm using epitope-specific mAbs is, however, limited. The 341 
specificity of mAbs is not exactly the same as that of the T cell epitopes, as mAbs only recognise 342 
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peptide sequences of 4-6 amino acids in length, which is substantially shorter than the 9 amino acid T 343 
cell epitopes that cause CD (Londono et al. 2013). Therefore, the identification of wheat genotypes 344 
with reduced CD toxicity using mAbs should be regarded as a preliminary screen, to be followed by 345 
screening of selected lines with more accurate methods.  346 
Salentijn et al. (2013) have examined the CD immunogenic potential of tetraploid durum wheat by 347 
deep sequencing of α-gliadin transcripts, including the sequences coding for both the N-terminal 348 
domain and the repetitive domain, where the CD epitopes occur, from developing grains. They found 349 
differences among varieties, but no variety was identified as safe for CD patients. Dubois et al. (2016) 350 
screened spelt lines by sequencing α-gliadin genes expressed in the developing grains. They saw no 351 
clear separation in the occurrence of epitopes between spelt and bread wheat accessions, although 352 
some spelt lines expressed more B-genome α-gliadins, which contain fewer epitopes. 353 
A direct approach would be to use quantitative proteomics to identify the gliadins in mature grains, as 354 
this would determine the exact amino acid sequence and the quantity of the proteins produced during 355 
grain development. However, this is complicated by the diversity of gluten genes in any single wheat 356 
variety, and the relative insensitivity of these proteins to the proteolysis step necessary for analysis. A 357 
method has recently been developed that enables identification and quantification of specific CD-358 
epitopes in chymotryptic gluten digests (van den Broeck et al. 2015). 359 
 360 
3.3. Reconstituting hexaploid bread wheat: synthetic hexaploids 361 
Overall, the genetic variation of the D genome in hexaploid bread wheat is much lower than the 362 
genetic variation present in the A and B genomes. This is consistent with the theory that the 363 
hybridisation that led to hexaploid bread wheat resulted in a strong genetic bottleneck (Reif et al. 364 
2005; Jones et al. 2013). Indeed, several studies have found high levels of genetic diversity among 365 
wild Ae. tauschii accessions (Wang et al. 2013; Jones et al. 2013). In order to introduce additional 366 
genetic diversity into bread wheat, programmes that recreate the hybridisation process to generate 367 
‘synthetic hexaploid wheat’ (SHW) have been undertaken at various institutes around the world, 368 
including the International Maize and Wheat Improvement Centre (CIMMYT, Mexico), NIAB (UK), 369 
and the Commonwealth Scientific and Industrial Research Organisation (CSIRO,Australia). The 370 
process involves hybridising T. turgidum spp. durum with Ae. tauschii, followed by rescue of the 371 
triploid embryo, and subsequent chromosome doubling using colchicine to generate hexaploid 372 
individuals. Careful selection of diverse Ae. tauschii donors can result in SHW accessions that 373 
maximise the D genome variation captured, and so increase the potential benefit of SHW in wheat 374 
breeding programmes. Ae. tauschii accessions which are low in CD-toxic gliadins could for instance 375 
be hybridised with two tetraploid durum wheat landraces that have been shown to possess a relatively 376 
low mAb response (van den Broeck et al. 2010b), to generate a low gluten immunogenic SHW wheat. 377 
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These SHWs could then be used in pre-breeding programmes for crossing with commercial varieties, 378 
combining screening for low gluten immunogenic progeny with the presence of competitive 379 
agronomic characters. 380 
 381 
3.4. Mutation breeding  382 
Mutation breeding is based on the random induction of genome-wide mutations, followed by selection 383 
of plants carrying mutations in the gene(s) of interest; products of mutation breeding can be released 384 
on the market without regulation. The type and frequency of mutations obtained in classical 385 
mutagenesis programmes depends on the method used (chemical or ionizing radiation), the type and 386 
concentration of mutagen, and the duration of the treatment, which are adjusted on a case by case 387 
basis. Polyploid crops in general tolerate higher mutation loads than diploid crops (Shu et al. 2011; 388 
Oladosu et al. 2016). This is certainly necessary for gliadin mutagenesis in wheat: stacking mutations 389 
in multiple gliadin genes into a single plant through crossing is very challenging, due to the number of 390 
gliadin genes and their close physical linkage, so this strategy can only be effective if each of the 391 
starting lines already contain many mutated gliadin genes. 392 
 393 
EMS 394 
Ethyl methane sulfonate (EMS) is a chemical mutation approach that primarily results in transitions of 395 
G/C to A/T nucleotides in the DNA. In the context of α-gliadin and γ-gliadin genes, EMS treatment 396 
may result in mis-sense mutations within epitopes, which could disrupt binding to the Antigen 397 
Presenting Cells, or non-sense mutations upstream of the epitopes which truncate the protein or 398 
prevent its translation. EMS mutations are detected using an approach termed Targeting Local Lesions 399 
IN Genomes (TILLING). Detection of induced mutations originally relied on enzyme-mediated 400 
cleavage of mismatched nucleotides (McCallum et al. 2000), but is now commonly done by DNA 401 
sequencing of either the complete genome or a subset of the genome, either produced with restriction 402 
enzymes or using approaches such as exome capture. Acevedo-Garcia et al. (2017) used TILLING to 403 
identify missense mutations in each of the three wheat Mildew Locus O (TaMLO) homoeologues, 404 
which were subsequently stacked to produce plants with enhanced, yet incomplete, resistance towards 405 
powdery mildew (Blumeria graminis f. sp. tritici (Bgt)). 406 
A simple screening system for EMS TILLING populations has been constructed in tetraploid (T. 407 
turgidum cv. Kronos) and hexaploid (T. aestivum cv. Cadenza) wheat. Both TILLING populations 408 
have recently been sequenced using exome capture (Krasileva et al. 2017), allowing identification of 409 
TILLING mutants in target genes via DNA sequence searches of online databases (www.wheat-410 
tilling.com/). Gluten gene mutants can be identified bioinformatically in these populations, but in 411 
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practice few mutated gliadin genes have been found. The high copy number and sequence similarity 412 
make it difficult to correctly assemble gliadin sequences. As a consequence, assembly of sequence 413 
reads from a mutated population runs the risk of combining reads with point mutations from multiple 414 
genes into single sequence assemblies. If filtered out, this could lead to an artificially low mutation 415 
frequency, but if not filtered, it could result in an over-estimation of the average number of mutations 416 
per gene. The use of Pacific Bioscience Circular Consensus Sequencing (PacBio CCS), which 417 
produces longer sequence reads, may solve some assembly issues. However, the resulting sequence 418 
data would likely still need to be combined with more accurate short read sequencing approaches (e.g. 419 
Illumina) to compensate for the relatively high PacBio sequencing error rate.  420 
 421 
Gamma irradiation 422 
Gamma (γ) -irradiation produces reactive oxygen species (ROS) that cause DNA oxidative damage or 423 
DNA single/double strand breaks. Double strand breaks are repaired by the cell’s non-homologous end 424 
joining (NHEJ) mechanism, which is a relatively error-prone process. Most errors lead to small 425 
deletions, although base-pair substitutions, inversions, and small insertions also may be found 426 
(Cockram et al. 2007; Morita et al. 2009). Gamma irradiation therefore has the potential to mutate 427 
epitopes, remove whole gliadin genes, or even delete multiple gliadin genes.  428 
In barley, γ-irradiated accession Risø 56 (lacking B-hordeins), Risø 1508 (lacking C-hordeins) and 429 
R118 (an Ethiopian derived line which lacks D-hordeins) have been intercrossed to produce an Ultra 430 
Low Gluten variety (ULG 2.0) with a reduction of hordein (gluten) content below 5 ppm, thus 431 
allowing it to be classified as ‘gluten-free’ (Tanner et al. 2016). Subsequent crossing and selection 432 
with commercial varieties resulted in a variety with good malting and brewing characteristics (now 433 
marketed as ‘Kebari’). Interestingly, in several countries the products made with this variety cannot 434 
legally be marketed as gluten-free, solely because it contains barley.  435 
In wheat a strategy to introduce similar resources into commercial breeding programs could be based 436 
on screening γ-irradiated hexaploid wheat populations, such as that created in the UK from the 437 
commercial cultivar Paragon. We are currently screening these lines for changes in their gluten pattern 438 
on acid PAGE protein gels (Cooke 1995), prior to further characterisation of a subset of lines using 439 
approaches such as RNA-seq, qPCR, and/or proteomics.  440 
 441 
Deletion lines 442 
Wheat deletion lines are available in which whole chromosomes, or parts of chromosomes, have been 443 
deleted by crossing monosomic with tetrasomic lines, or by introgression of alien addition or 444 
translocation lines into cv. ‘Chinese Spring’ to induce deletions (Endo and Gill, 1996). A set of these 445 
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hexaploid wheat cv. ‘Chinese Spring’ deletion lines has been used to test the effects of individual 446 
deletions on the reduction of CD epitopes and on technological properties. A deletion line missing the 447 
short arm of chromosome 6D (6DS) in which the 6D α-gliadin locus had been deleted, was found to 448 
have strongly decreased mAb responses against Glia-α1 and Glia-α3 epitopes (van den Broeck et al. 449 
2009). The absence of these α-gliadin proteins also led to a significant change in dough mixing 450 
properties and dough rheology, as the dough became stiffer and less elastic. In contrast, the deletion of 451 
the ω-gliadins, γ-gliadins and LMW-glutenin subunits on chromosome 1DS removed some epitopes, 452 
but the technological properties were retained (van den Broeck et al. 2009).  453 
 454 
3.5. Transgenic approaches to reduce CD toxicity 455 
Until recently, wheat was considered a challenging crop for genetic transformation; particle 456 
bombardment was routinely used for delivery of gene constructs, despite its many drawbacks in the 457 
quality of plants generated, which included multiple insertions with complex rearrangements. 458 
Furthermore, only a limited range of germplasm could be utilised. The development of supervirulent 459 
Agrobacterium tumefaciens strains (Wu et al. 2008), plus changes to media components and the 460 
introduction of new techniques (Wu et al. 2003; Risacher et al. 2009) improved efficiency. However, 461 
the major breakthrough was made by Ishida et al. (2014), using the US soft white wheat, Fielder. This 462 
new technology is implemented at NIAB and has been used to both extend the range of UK spring and 463 
winter germplasm which can be transformed, and to support a high throughput wheat transformation 464 
platform. 465 
 466 
Gene silencing using RNA interference 467 
RNA interference (RNAi) is a conserved biological process initially identified as a plant defence 468 
mechanism, in which a viral double-stranded RNA (dsRNA) is cleaved, silencing viral gene 469 
expression and inhibiting further replication (Ratcliff et al. 1997). It has since been demonstrated that 470 
genetic transformation of plants with a construct encoding a dsRNA molecule similar to an 471 
endogenous plant single-stranded mRNA, triggers silencing of that specific plant gene (Waterhouse 472 
and Helliwell, 2003). 473 
Two research groups have successfully silenced gliadin expression using RNAi. Becker et al. (2012) 474 
silenced α-gliadins, eliminating 20 different storage proteins from the grain, whereas Gil-Humanes et 475 
al. (2010) down-regulated gliadins from all groups in bread wheat, with an average reduction of 92.2% 476 
in the R5 mAb assay. T cell tests demonstrated a 10-100-fold reduction in DQ2 and DQ8 epitopes 477 
from α-gliadins, γ-gliadins and ω-gliadins. Indeed, total gluten extracts of three transgenic wheat lines 478 
did not to stimulate T cell clones. Down-regulation of γ-gliadins resulted in an increase of other gluten 479 
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proteins in the grains (Pistόn et al. 2011), but little or no effect was found on dough strength or gluten 480 
and starch properties (Pistόn et al. 2011; Gil-Humanes et al. 2012; 2014).   481 
RNAi has also been used to suppress the DEMETER (DME) homoeologues in wheat (Wen et al. 482 
2012). The DME gene encodes a 5-methylcytosine DNA glycosidase that demethylates the promotor 483 
regions of gliadins and LMW-glutenins in the wheat endosperm. This demethylation is essential for 484 
activation of the genes during endosperm development. DME RNAi transgenic plants showed a high 485 
degree of DME transcript suppression, resulting in >75% reduction in the amount of immunogenic 486 
prolamins.  487 
Providing their agronomic properties and yields are acceptable, such RNAi wheat lines may become 488 
candidates for the production of wheat-based products for ‘gluten-free’ or ‘low-in-gluten’ diets. 489 
However, it should be noted that these strategies require a stable integration of the RNAi cassette into 490 
the genome, thus resulting in a genetically modified (GM) plant. It is therefore subject to relevant 491 
national and international GM regulations, with the accompanying long, expensive, and uncertain 492 
procedure for market approval.  493 
 494 
Targeted mutagenesis to generate small indels and to delete genes 495 
In contrast to mutation breeding, genome (gene) editing approaches aim to induce mutations only 496 
within specific targets. These methods include Meganucleases, Zincfinger nucleases, TALENs and 497 
CRISPR-Cas9. The regulatory status of plants and plant products derived from gene editing is 498 
currently unclear in the European Union (Sprink et al. 2016). The current method of choice is 499 
CRISPR-Cas9 due to its ease of use (e.g., Schaart et al. 2016). The CRISPR-Cas9 system was 500 
originally described as a bacterial defence mechanism against viral infections (Barrangou et al. 2007) 501 
and has since been customised to induce mutations and deletions at specific locations within a target 502 
gene in animals and plants (Zhou et al. 2014; Schaart et al. 2016). Mutations can be induced by 503 
introducing genomic RNA (gRNA) complementary to the gene of interest, plus an expression cassette 504 
to express the Cas9 endonuclease protein. The 20-mer gRNA directs the Cas9 nuclease to the target 505 
site within the gene of interest, where the nuclease generates a double strand DNA break, three bases 506 
upstream of a specific protospacer adjacent motif (PAM). In plants, repair by NHEJ can result in 507 
insertion/deletions (indels) and other mutations, that can result in beneficial phenotypes (Belhaj et al. 508 
2013; van de Wiel et al. 2017).  509 
CRISPR-Cas9 and other site-directed nucleases have been successfully used to target homeologous 510 
genes in diploid and polyploid crops (Brooks et al. 2014; Lawrenson et al. 2015). In potato, the four 511 
copies of Granule-bound starch synthase (GBSS) have been simultaneously modified to alter starch 512 
composition in tetraploid potato (Andersson et al. 2017). In bread wheat, the TALEN system was used 513 
to simultaneously mutate the three homoeologs of an TaMLO gene (Wang et al. 2014). Using a 514 
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Cas9/guide ribonucleoprotein complex in plant callus, protoplasts and immature embryos, 515 
homeologous genes were successfully edited in hexaploid and durum wheat (Zhang et al. 2016; Liang 516 
et al. 2017). In this system no foreign DNA is added to the plant cell, so plants developed in this 517 
manner might not be regulated as GM, as was recently propositioned by the U.S. Department of 518 
Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) in its proposed revision 519 
of regulations (USDA, 2017). 520 
With these examples, it should also be feasible to modify and/or delete gliadin genes from hexaploid 521 
wheat. Such experiments are ongoing at NIAB and elsewhere.  In theory, several types of mutations 522 
could be generated in the gliadin genes. Small indels, within or upstream of the epitope region, can 523 
generate premature stop codons resulting in truncated proteins that lack CD epitopes or within 524 
modified epitopes which are no longer immunogenic. Moreover, genes of the α-, γ- and ω- gliadin 525 
families are each grouped at single loci on the short arms of the group 6 and 1 chromosomes, 526 
respectively. The α-gliadin Gli-2 loci contains α-gliadin interspersed with retrotransposons (Gu et al. 527 
2004). The γ -gliadin locus also includes other prolamin and non-prolamin genes (Gao et al.  2007). 528 
Cas9-mediated double strand breaks generated simultaneously in at least two gliadin genes on the 529 
same chromosome may result in a deletion of the intervening genes. Similarly, multiplexing gRNAs to 530 
target different sites within one gliadin gene could, together with a high mutation rate, delete only the 531 
immunogenic epitopes from the gliadin protein.  532 
Following wheat transformation with the gliadin gene editing construct, T1 seed could be analysed by 533 
Acid-PAGE separation of storage proteins, allowing rapid identification of plants with modified 534 
gliadin profiles. Lines of interest could then be further analysed using methods such as deep 535 
sequencing of the genome, digital drop real-time PCR to determine gliadin copy number, and RNA-536 
seq of developing grains to determine gene expression profiles. Jouanin et al. (in preparaion) are 537 
currently using a process termed ‘Gluten genes Enrichment and Sequencing’ (GlutEnSeq), a protocol 538 
based on REnSeq methods (Jupe et al. 2013). This approach uses exome capture to enrich for gluten 539 
gene DNA from lines of interest for targeted re-sequencing, preferably using a long read technology 540 
such as PacBio. Proteomics methods such as LC-QTOF-MSMS could be used to generate information 541 
on the composition of the gliadins produced in mutant lines, to quantify epitope levels, and to 542 
determine the occurrence of amino acid changes in epitope-harbouring peptide fragments.  543 
 544 
5. Prospects for the low gluten immunogenicity strategies 545 
The food processing and wheat breeding strategies described represent two major routes for the 546 
development of cereal products with low gluten immunogenicity. Gluten-free products, made without 547 
wheat, barley or rye, are now increasingly found on grocery store shelves. However, these products 548 
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typically require the inclusion of numerous additives, resulting in products that are often less healthy 549 
than gluten-based equivalents. To overcome this issue, other strategies have to be deployed. 550 
Malting may be one of the most applicable methods for large-scale preparation of products with low 551 
gluten immunogenicity in the food processing industry, and it can even enhance sourdough 552 
fermentation when the malting process is not fully stopped. Similarly, sourdough is a traditional 553 
method used to increase loaf volume for bread baking which is possible to implement at industrial 554 
scale. Sourdough can also be combined with malting for further reduction of gluten immunogenicity. 555 
However, in addition to being more time consuming, sourdough has a taste that may not be widely 556 
accepted by consumers.  557 
While the separation of gliadins from glutenins, followed by substitution of gliadins for non-558 
immunogenic oat avenins, is possible at a laboratory scale, large-scale implementation could be 559 
challenging and would require considerable infrastructure. From another perspective, the labelling and 560 
reduction in the use of vital gluten as an additive, used as source of protein to improve food structure, 561 
is a simple approach that would improve the healthiness of gluten-sensitive patients. Unlike GM 562 
breeding techniques, most of the candidate food processing techniques for making low gluten-563 
immunogenic products are already implemented, and do not arouse ethical and political issues. 564 
From a wheat breeding perspective, very few polyploid wheat accessions show low gliadin 565 
immunogenicity, and those that do lack the agronomic characteristics required for commercial 566 
varieties. Introgression of the multiple low immunogenic gliadin loci involved into commercial 567 
varieties would be a complex undertaking. Since the expected result would only be a low-568 
immunogenic line, not a CD-safe wheat, it is not anticipated to be a likely near-term target in wheat 569 
breeding. 570 
Mutation breeding represents an attractive option to create wheat with low gluten immunogenicity. 571 
EMS TILLING on members of large gene families is challenging. Again multiple mutations are 572 
necessary, but if these occur in multiple plants then a programme of backcrossing followed by 573 
recurrent self-pollination would be required to remove background mutations, while retaining as many 574 
homozygous gliadin mutations as possible. However, as the gliadins are closely linked on 575 
chromosome 1 and 6, the recombination events required to combine all mutations in a single genetic 576 
background might be very rare. Induced mutations using γ-irradiation would be a more tractable 577 
approach, since multiple gliadin genes may be removed in single deletion events. This approach has 578 
been successfully undertaken in the diploid crop barley, where inter-crossing γ-irradiated lines, each 579 
missing a different prolamin gene family, generated an Ultra Low Gluten line that was successfully 580 
crossed with commercial varieties (Tanner et al. 2016), leading to a commercial variety with less than 581 
20 ppm gluten. In theory, this line could be used for breeding more low-gluten barley varieties, 582 
although it would represent a major bottleneck for genetic diversity around these deletions. The 583 
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variety also comes with a yield penalty. It is not expected that this line will be used by other breeders 584 
to generate low-gluten barley in the short term (Tanner, pers. comm). However, the case for wheat 585 
may be stronger, as CD patients encounter wheat gluten in many food products, but can easily avoid 586 
barley by drinking only gluten-free beer. 587 
The use of RNAi in wheat has been shown to be very efficient in decreasing the amount of gliadins 588 
expressed in the grain, without greatly altering dough properties. Nonetheless, the RNAi construct 589 
must be retained in the plant genome, resulting in a GM plant. Multiple factors restrict the commercial 590 
feasibility of using GM crops, including the costs of the regulatory process in those countries that 591 
allow GM crops (Laursen, 2016). However, this may not be the case with CRISPR-Cas9 technology, 592 
as after having generated inheritable mutations in target genes, the T-DNA can be crossed out. 593 
Whether the resulting products, which do not contain foreign DNA, will be regulated as GM plants, is 594 
under debate (Sprink et al. 2016). In some countries, process-based regulation may define them as 595 
GM, whereas other countries with a more product-based approach may consider them to be identical 596 
to plants produced by conventional or mutation breeding. The European Food Safety Authority 597 
(EFSA) GMO panel (2015) considered the use of site-directed nucleases for inducing small deletions 598 
or insertions at a precisely defined location in the genome (SDN-1) as a form of mutagenesis. 599 
Acceptance by consumers may also be an issue (Ishii and Araki, 2016) but acceptance of products that 600 
are tailored to the needs of specific groups of consumers (e.g., hypoallergenic fruits, nuts etc.) is 601 
probably much higher than that of products tailored to the needs of producers or the general public 602 
(Schenk et al. 2008; 2011; Kronberger et al. 2014). 603 
In the future, low gluten immunogenicity may become one of many traits included in commercial 604 
breeding programs. Achieving low gluten-immunogenic wheat, and ultimately food products, will 605 
require a great deal of effort and is likely to require changes in industrial grain and food processing 606 
processes. Despite these challenges, the importance of wheat (and other gluten-containing 607 
immunogenic grains) in the human diet, along with the increasing worldwide incidence of 608 
immunogenic diseases such as CD, means that it is imperative that these challenges are now 609 
addressed.  610 
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Figure legends. 1000 
Figure 1. Food supply chains producing gluten-free or coeliac-safe(r) products. 1001 
Depicted are simplified food supply chains comprising of two steps, plant breeding and food 1002 
processing, leading to the final food product. Three variants, a), b) and c), of this food supply 1003 
chain can be envisaged, depending on the step at which efforts are made to generate gluten-free 1004 
or coeliac-safe(r) products and whether the process includes wheat ingredients or not. These three 1005 
variants are presented here in the same order as described in the paper. a) Gluten-free products 1006 
are generated using substitutions for wheat to avoid the presence of its immunogenic gluten 1007 
fraction. b) Coeliac-safer of celiac-safe products could be made at the food-processing step by 1008 
processing wheat grains to decrease their immunogenic gluten fraction before proceeding to 1009 
processing of the final product. c) Coeliac-safer or coeliac-safe products could be made based on 1010 
plant breeding of wheat varieties with reduced immunogenic gluten fraction, used in a standard 1011 
grain processing and final food product processing. Note that b) and c) can complement each 1012 
other to achieve a further reduction of gluten immunogenicity. 1013 
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